KB
ISEE

Kimelman & Baird’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Kimelman & Baird’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,650
Closed -$287K – 114
2015
Q4 		$287K Buy
+3,650
New +$211K 0.05% 89

Other funds holding ISEE

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Kimelman & Baird's ISEE Position: Q1 2016 in Review

Kimelman & Baird sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2016, closing a stake of 3,650 shares — an estimated $287K sold.

Kimelman & Baird first reported a position in ISEE in Q4 2015 and held it in 1 quarter. The position peaked at $287K in Q4 2015. 162 funds tracked by Wall St. Rank hold ISEE as of Q1 2016.

  • Kimelman & Baird reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Kimelman & Baird sold 3,650 IVERIC bio, Inc. Common Stock shares in Q1 2016, an estimated $287K.
  • Kimelman & Baird first reported a position in IVERIC bio, Inc. Common Stock in Q4 2015 and held it in 1 quarter.
  • Kimelman & Baird's IVERIC bio, Inc. Common Stock position peaked at $287K in Q4 2015.
  • 162 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2016.

Based on Kimelman & Baird's 13F filing for Q1 2016, filed 13 May 2016.